We report a heterozygous case of familial qualitative deficiency of antithrombin III associated with cerebral infarction.
uantitative deficiency of antithrombin HI (AT-III) with a high incidence of thrombosis was first described by Egeberg, 1 and Sas et al 2 madelhe first report of a qualitative AT-III defect in a family with spontaneous thromboembolism. More than 30 families with AT-III abnormalities have now been reported, and the variants have been divided into five subtypes. 34 AT-III deficiencies have been shown to be associated with a high incidence of thrombotic disorder; the prevalence of thromboembolism is reported to be about 50%. A striking difference, however, has been noted for subtype lie. There is a very low prevalence in heterozygous cases (6%) and a high prevalence in homozygous cases (100%). 5 We describe the case of a young man who suffered recurrent cerebral infarction and was shown to be a heterozygote of the subtype lie AT-III deficiency.
Case Report
The proband was a 33-year-old male without previous episodes of cerebrovascular disorder. In November 1985, at age 28, he developed numbness and weakness in his right hand that disappeared in 10 minutes. After that he experienced several recurrent transient ischemic attacks (TIAs). In February 1986, he was admitted to our hospital for further evaluation of his TIAs. Cerebral computed tomography (CT) disclosed a low-density area in the left frontal lobe ( Figure 1A ). Cerebral angiography showed branch occlusion of the right anterior cerebral artery and focal stenosis in the proximal portion of the left middle cerebral artery (Figure 2A ). The etiology, however, was undetermined at that time. On July 14, 1989, despite antiplatelet treatment, he suddenly experienced weakness in his left hand that improved in 1 minute. On July 16, he was again admitted to our hospital because of convulsion and loss of consciousness. He had smoked 30-40 cigarettes daily for 14 years. No consanguinity was found in his family history.
On admission, physical examination revealed obesity. His height was 177 cm and weight was 89 kg. He showed slightly disturbed comprehension and mild dysarthria, left hemiparesis, and bilateral Babinski's sign.
Results of routine laboratory examinations were all in the normal range except for a low level of high density lipoprotein cholesterol. Serological tests for antinuclear antibodies, lupus anticoagulant, and anticardiolipin antibodies were negative. An oral glucose tolerance test showed mild hyperglycemia. Cerebrospinal fluid findings were normal. Hemostatic test results for coagulation time, prothrombin time, activated partial thromboplastic time, fibrinogen, fibrin degradation products, plasminogen activity, protein C activity, protein S activity, and heparin cofactor II activity were all within the normal range. Platelet activation studies were normal. A roentgenogram of the chest, an electrocardiogram, and a transesophageal echocardiogram were normal. Brain CT disclosed low-density areas in the bilateral frontal lobes ( Figure IB) . On day 5 after admission, his signs and symptoms improved, leaving slight dysarthria. On August 13, he suddenly developed numbness and The plasma concentration and functional activity of AT-III were measured in the proband and his parents ( Table 1 ). The AT-III antigen concentration and progressive antithrombin activity were in the normal range for all of them. In contrast, heparin cofactor activity was low in the patient (67%) and his father (55%). Twodimensional crossed immunoelectrophoresis of plasma in the absence of heparin showed no difference between the proband and his parents, whereas in the presence of heparin, two peaks were found in the patient and his father. Affinity chromatography on heparin sepharose of the patient and his father revealed two AT-III populations, one of which was devoid of heparin cofactor activity (Figure 3 ). Nucleotide sequence analysis of the proband's deoxyribonucleic acid showed no mutation in exons II and VI of AT-III.
Discussion
Congenital AT-III abnormality is a heterogeneous disorder classifiable into five subtypes 3 -4 : type I, low functional and immunological AT-III; subtype la, reduced synthesis, increased turnover of a normal molecule, or both; subtype Ib, reduced synthesis or turnover of AT-III or both, with abnormal heparin affinity; type II, low functional but normal immunological AT-III; subtype Ha, functional abnormalities involving both the active and the heparin-binding sites; subtype lib, functional abnormalities limited to the active site; and subtype lie, functional abnormalities limited to the heparin-binding site. The patient was classified as having the subtype lie AT-III deficiency because of his normal AT-III antigen concentration, progressive antithrombin activity, and decreased heparin cofactor activity. In addition, he was considered a heterozygote because no consanguinity was found in his family, and the plasma from his mother showed a single peak with the same mobility as that of the control in the presence and absence of heparin. So far, 18 families with subtype lie deficiency have been reported. 6 - 25 We reviewed the cases of 80 patients from 17 of these families for whom clinical data were available. A history of arterial or venous thrombosis or both was obtained for 15 of the 80 patients studied.
Arterial thrombosis was present only in nine patients, four of whom were heterozygotes. Only three showed cerebral thrombosis, and they were homozygous for an arguiine 4 7-*cysteine mutation ( 25 The common clinical features in these cases, including the one reported here, are the occurrence of ischemic stroke in young adults and occlusion of the truncal rather than perforating arteries. The striking thing about our patient may be that he is a heterozygote who has a new mutation; nucleotide sequence analysis of the proband's deoxyribonucleic acid showed no mutation in exons II and VI of AT-III. We are now studying all nucleotide sequence analyses of the proband's AT-III. Recently, the heparin-binding site was found to involve two distinct regions in the secondary structure of AT-III, encompassing arginine 47 and arginine,^. 26 The AT-III abnormality of our patient, therefore, seems to be associated with the latter region.
AT-III deficiency is known to predispose individuals to venous thrombosis, but its relation to arterial disease is not established. Whether reduced AT-III activity is the predisposing factor of stroke is still a matter of controversy.
27
- 29 The presumed predisposing factors in our patient are smoking, obesity, low high density lipoprotein cholesterol level, and a mild glucose intolerance. The pathogenesis of his recurrent cerebral thrombosis is undetermined. Hart and Kanter 30 reported that most patients with congenital AT-III deficiency and stroke have had previous venous thrombosis, with rare possible exceptions.
14 Thereafter, another exception was reported. 31 We conclude, therefore, that a subtype lie AT-III abnormality, even in heterozygotes, may cause ischemic stroke in young adults when associated with other predisposing factors. 
